Consensus Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Real-time Estimate Cboe BZX Other stock markets 11:48:25 2024-05-13 am EDT			5-day change	1st Jan Change
40.64 ^USD	-1.65%		-10.91%	+163.78%

May. 10	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating	MT
May. 09	Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Vera Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

617d107aac9179a018c89cc66fad1f32._yeTD0dfcZ-FbnfZjZ42JzWSQXqFPDlJpE6ntgypgdk.i3-rWnMbC-bxIDnt_epGVH3XFAPgfk4h8AjR0H_46LSybtVGCCUu1MY-Og~9ec2b3b8fcaf4fe9599a71218de6107c

Analyst Recommendations on Vera Therapeutics, Inc.

Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating	May. 10	MT
Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral rating	Mar. 21	MT
Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating	Jan. 26	MT
Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29	Jan. 26	MT
Wedbush Raises Vera Therapeutics' Price Target to $21 From $16, Keeps Neutral Rating	Jan. 26	MT
Oppenheimer Initiates Coverage on Vera Therapeutics With Outperform Rating, $26 Price Target	Jan. 25	MT
Cantor Fitzgerald Starts Vera Therapeutics With Overweight Rating	Jan. 08	MT
Raymond James Initiates Vera Therapeutics at Outperform Rating With $29 Price Target	Dec. 18	MT
Jefferies Upgrades Vera Therapeutics to Buy From Hold, Adjusts Price Target to $26 From $18	Nov. 10	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $25 From $10, Maintains Buy Rating	23-09-26	MT
Guggenheim Initiates Vera Therapeutics With Buy Rating, $27 Price Target	23-08-16	MT
Wedbush Lifts Vera Therapeutics' Price Target to $16 From $12, Keeps Neutral Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $10 From $11, Keeps Buy Rating	23-05-12	MT
Wedbush Raises Vera Therapeutics' Price Target to $9 From $6, Keeps Neutral Rating	23-05-12	MT
JPMorgan Lowers Price Target on Vera Therapeutics to $22 From $38, Maintains Overweight Rating	23-04-12	MT
HC Wainwright Adjusts Vera Therapeutics' Price Target to $11 From $15, Keeps Buy Rating	23-03-29	MT
Wedbush Lowers Vera Therapeutics' PT to $6 From $8, Updates Estimates to Incorporate February Secondary Offering Proceeds; Keeps Neutral Rating	23-03-29	MT
Jefferies Downgrades Vera Therapeutics to Hold From Buy, Slashes Price Target to $6 From $32	23-01-04	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $15 From $36, Maintains Buy Rating	23-01-04	MT
Wedbush Downgrades Vera Therapeutics to Neutral From Outperform, Says Shares Likely Range-Bound in Near Term; Lowers PT to $8 From $33	23-01-04	MT
JPMorgan Adjusts Price Target on Vera Therapeutics to $38 From $35, Maintains Overweight Rating	22-11-18	MT
HC Wainwright Lifts Price Target on Vera Therapeutics to $36 From $35, Reiterates Buy Rating	22-08-22	MT
Wedbush Lifts Price Target on Vera Therapeutics to $33 From $32, Keeps Outperform Rating	22-08-10	MT
JPMorgan Starts Vera Therapeutics at Overweight With $35 Price Target	22-07-12	MT
HC Wainwright Starts Vera Therapeutics at Buy With $35 Price Target	22-05-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.32 USD

Average target price

56.7 USD

Spread / Average Target

+37.22%

High Price Target

107 USD

Spread / Highest target

+158.95%

Low Price Target

25 USD

Spread / Lowest Target

-39.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vera Therapeutics, Inc.

Wedbush
Oppenheimer
Raymond James
Cantor Fitzgerald
Jefferies & Co.
HC Wainwright
Guggenheim
JPMorgan Chase
Cowen
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar